{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:30:17Z","timestamp":1791819017969,"version":"4.3.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.chest.2017.05.015","type":"journal-article","created":{"date-parts":[[2017,5,28]],"date-time":"2017-05-28T23:35:02Z","timestamp":1496014502000},"page":"1283-1295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Lung Manifestations in the Rheumatic Diseases"],"prefix":"10.1016","volume":"152","author":[{"given":"Tracy J.","family":"Doyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Dellaripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.chest.2017.05.015_bib1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1164\/rccm.200607-912OC","article-title":"Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes","volume":"175","author":"Park","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2017.05.015_bib2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1378\/chest.13-2388","article-title":"Pulmonary function and survival in idiopathic vs\u00a0secondary usual interstitial pneumonia","volume":"146","author":"Strand","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.chest.2017.05.015_bib3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"21","key":"10.1016\/j.chest.2017.05.015_bib4","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1017","key":"10.1016\/j.chest.2017.05.015_bib5","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1259\/bjr\/54532316","article-title":"The reversed halo sign: update and differential diagnosis","volume":"85","author":"Godoy","year":"2012","journal-title":"Br J Radiol"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/rheumatology\/keq410","article-title":"Comparison between cryptogenic organizing pneumonia and connective tissue disease-related organizing pneumonia","volume":"50","author":"Yoo","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib7","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1055\/s-0032-1325156","article-title":"Lymphocytic interstitial pneumonia and other benign lymphoid disorders","volume":"33","author":"Tian","year":"2012","journal-title":"Semin Respir Crit Care Med"},{"issue":"5 Pt 1","key":"10.1016\/j.chest.2017.05.015_bib8","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1164\/ajrccm.157.5.9710018","article-title":"Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings","volume":"157","author":"Perez","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1183\/09031936.00091608","article-title":"Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis","volume":"33","author":"Devouassoux","year":"2009","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.chest.2017.05.015_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.4187\/respcare.01857","article-title":"Coexistence of bronchiectasis and rheumatoid arthritis: revisited","volume":"58","author":"Wilczynska","year":"2013","journal-title":"Respir Care"},{"issue":"10","key":"10.1016\/j.chest.2017.05.015_bib11","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.rmed.2012.06.020","article-title":"Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis","volume":"106","author":"Wilsher","year":"2012","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2017.05.015_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.38201","article-title":"Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis","volume":"66","author":"Reynisdottir","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.chest.2017.05.015_bib13","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.semarthrit.2006.03.002","article-title":"Rheumatoid pleural effusion","volume":"35","author":"Balbir-Gurman","year":"2006","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.chest.2017.05.015_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3899\/jrheum.121048","article-title":"Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies","volume":"40","author":"Henderson","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.chest.2017.05.015_bib15","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/13993003.00150-2015","article-title":"An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features","volume":"46","author":"Fischer","year":"2015","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.chest.2017.05.015_bib16","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1164\/rccm.2106012","article-title":"Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome","volume":"165","author":"Bouros","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2017.05.015_bib17","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1378\/chest.08-0053","article-title":"Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival","volume":"134","author":"Fischer","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2017.05.015_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1586\/ers.11.18","article-title":"Pulmonary arterial hypertension associated with systemic sclerosis","volume":"5","author":"Mathai","year":"2011","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"10.1016\/j.chest.2017.05.015_bib19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24267","article-title":"Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease","volume":"60","author":"Mathai","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.chest.2017.05.015_bib20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.15-0003","article-title":"Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis","volume":"148","author":"Ryerson","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.chest.2017.05.015_bib22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s13075-015-0872-2","article-title":"Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials","volume":"17","author":"Khanna","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.chest.2017.05.015_bib23","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.chest.2017.05.015_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2017.05.015_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13075-016-1203-y","article-title":"Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease","volume":"18","author":"Volkmann","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.chest.2017.05.015_bib26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.chest.2017.05.015_bib27","doi-asserted-by":"crossref","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib28","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2017.05.015_bib29","first-page":"100","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J\u00a0Bras Pneumol"},{"issue":"9","key":"10.1016\/j.chest.2017.05.015_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.chest.2017.05.015_bib31","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/acr.21985","article-title":"Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis","volume":"65","author":"Chen","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.chest.2017.05.015_bib32","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22498","article-title":"Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease","volume":"67","author":"Narang","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.chest.2017.05.015_bib34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/art.24372","article-title":"Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis","volume":"61","author":"Le Goff","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.chest.2017.05.015_bib35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1164\/rccm.201004-0622OC","article-title":"Rheumatoid arthritis\u2013interstitial lung disease\u2013associated mortality","volume":"183","author":"Olson","year":"2011","journal-title":"Am J Resp Crit Care Med"},{"issue":"9","key":"10.1016\/j.chest.2017.05.015_bib36","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1093\/rheumatology\/keu165","article-title":"Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2014a large multicentre UK study","volume":"53","author":"Kelly","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.chest.2017.05.015_bib37","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1183\/13993003.00357-2015","article-title":"Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease","volume":"47","author":"Solomon","year":"2016","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.chest.2017.05.015_bib38","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/annrheumdis-2012-203160","article-title":"Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease","volume":"73","author":"Giles","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.chest.2017.05.015_bib39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/art.37881","article-title":"Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease","volume":"65","author":"Harlow","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.chest.2017.05.015_bib40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.chest.2017.05.015_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.38904","article-title":"Biomarkers of rheumatoid arthritis-associated interstitial lung disease","volume":"67","author":"Chen","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.chest.2017.05.015_bib42","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers","volume":"191","author":"Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.chest.2017.05.015_bib44","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.chest.2017.05.015_bib45","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor alpha agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.chest.2017.05.015_bib46","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/rheumatology\/ker236","article-title":"Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study","volume":"50","author":"Arulkumaran","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.chest.2017.05.015_bib47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/rheumatology\/kev286","article-title":"Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort","volume":"55","author":"Schirmer","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.chest.2017.05.015_bib48","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1093\/rheumatology\/kew224","article-title":"BSR and BHPR guideline for the treatment of systemic sclerosis","volume":"55","author":"Denton","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.chest.2017.05.015_bib49","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.chest.2017.05.015_bib50","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3899\/jrheum.080447","article-title":"Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma","volume":"36","author":"Garin","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.chest.2017.05.015_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.semarthrit.2016.02.004","article-title":"Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study","volume":"46","author":"Richardson","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"22","key":"10.1016\/j.chest.2017.05.015_bib52","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.chest.2017.05.015_bib53","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2017.05.015_bib54","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","article-title":"An open-label, phase ii study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial","volume":"43","author":"Khanna","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.chest.2017.05.015_bib55","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.chest.2017.05.015_bib56","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD)\u2014report from OMERACT CTD-ILD Working Group","volume":"42","author":"Khanna","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib57","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/thoraxjnl-2013-204202","article-title":"Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials","volume":"69","author":"Saketkoo","year":"2014","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.chest.2017.05.015_bib58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J\u00a0Rheumatol"},{"issue":"25","key":"10.1016\/j.chest.2017.05.015_bib59","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2017.05.015_bib60","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2017.05.015_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2016.11.007","article-title":"Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease","volume":"121","author":"Oldham","year":"2016","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2017.05.015_bib62","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/bmt.2016.211","article-title":"Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis","volume":"52","author":"Del Papa","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.chest.2017.05.015_bib63","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/rheumatology\/kew259","article-title":"Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests","volume":"55","author":"Kloth","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.chest.2017.05.015_bib64","doi-asserted-by":"crossref","unstructured":"Courtwright AM, El-Chemaly S, Dellaripa PF, Goldberg HJ. Survival and outcomes after lung transplantation for non-scleroderma connective tissue-related interstitial lung disease [published online ahead of print December 31, 2016. J Heart Lung Transplant. http:\/\/dx.doi.org\/10.1016\/j.healun.2016.12.013.","DOI":"10.1016\/j.healun.2016.12.013"},{"issue":"6","key":"10.1016\/j.chest.2017.05.015_bib65","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1513\/AnnalsATS.201512-801ED","article-title":"Lung transplantation in scleroderma. Time for the pendulum to swing?","volume":"13","author":"Eberlein","year":"2016","journal-title":"Ann Am Thorac Soc"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217309637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369217309637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:37:46Z","timestamp":1757921866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369217309637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0012369217309637"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2017.05.015","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung Manifestations in the Rheumatic Diseases","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2017.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}